Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262321 · ClinicalTrials.gov registry record · Phase 2
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
A Phase 2 study of Radiotherapy and Stage 4 NSCLC, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06262321 is a Phase 2 study of Radiotherapy and Stage 4 NSCLC that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 48 participants, below the 91-participant average among 4 other Radiotherapy trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06262321, a Phase 2 study of Radiotherapy and Stage 4 NSCLC, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
Conditions Studied
Interventions
- RADIATION Prophylactic Palliative Radiotherapy
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06262321
The ClinicalTrials.gov registry entry for NCT06262321 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 4 other Radiotherapy trials with a reported enrollment target (47% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Radiotherapy appearing as the primary indexed condition, and to 1 intervention - of which Prophylactic Palliative Radiotherapy is the first listed.
NCT06262321 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06262321 about?
NCT06262321 is a clinical study titled "Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax". Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
What is the current status of trial NCT06262321?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-05-15. Estimated completion is 2029-02-01.
What conditions does trial NCT06262321 study?
This clinical trial studies the following conditions: Radiotherapy, Stage 4 NSCLC.
What interventions are being tested in trial NCT06262321?
The interventions under investigation include: Prophylactic Palliative Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT06262321?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06262321 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiotherapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.